R&D Investment Toward Product Launch
First written in FY2021-Q2. 12 of 14 entries say "Restated". Latest entry: FY2026-H1.
3 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The amount of R&D activities across the Group for the interim consolidated accounting period was ¥24.283 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
R&D expenses of ¥24.283 million were disclosed, and it was stated that there had been no material changes in the status of R&D activities. - FY2025-H1RestatedAnnual report
「The amount of R&D activities across the Group for the interim consolidated accounting period was ¥27.198 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
R&D expenses of ¥27.198 million were disclosed, and it was stated that there had been no material changes in the status of R&D activities. - FY2024-Q3RestatedAnnual report
「The amount of R&D activities across the Group for the first 9 months of the current fiscal year was ¥45.208 million. There were no material changes in the status of the Group's R&D activities during the third quarter of the current fiscal year.」
R&D expenses of ¥45.208 million were disclosed, and it was stated that there had been no material changes in the status of R&D activities. - FY2024-Q2RestatedAnnual report
「The amount of R&D activities across the Group for the first half of the current fiscal year was ¥30.007 million. There were no material changes in the status of the Group's R&D activities during the first half of the current fiscal year.」
R&D expenses of ¥30.007 million were disclosed, and it was stated that there had been no material changes in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「The amount of R&D activities across the Group for the first quarter of the current fiscal year was ¥15.559 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current fiscal year.」
R&D expenses of ¥15.559 million were disclosed, and it was stated that there had been no material changes in the status of R&D activities. - FY2023-Q3RestatedAnnual report
「The amount of R&D activities across the Group for the first 9 months of the current fiscal year was ¥22.831 million. On 1 November 2022, the Company established and began operating the AXXZIA R&D Center, an R&D facility for cosmetics and quasi-drugs, as a new internal division.」
R&D activities have continued, and cumulative R&D expenses of ¥22.831 million were disclosed. The establishment and launch of the R&D center had already been reported through the previous quarter, and there were no milestones such as the completion of a new facility. - FY2023-Q2AdvancedAnnual report
「The amount of R&D activities across the Group for the first half of the current fiscal year was ¥14.690 million. On 1 November 2022, the Company established and began operating the AXXZIA R&D Center, an R&D facility for cosmetics and quasi-drugs, as a new internal division.」
R&D expenses of ¥14.690 million were disclosed, and the AXXZIA R&D Center, an R&D facility for cosmetics and quasi-drugs, was established and began operating on 1 November 2022. - FY2023-Q1RestatedAnnual report
「The amount of R&D activities across the Group for the first quarter of the current fiscal year was ¥6.206 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current fiscal year.」
R&D activities have continued, and the amount for the first quarter of the current fiscal year was disclosed as ¥6.206 million, while it was stated that there had been no material changes in the status of the activities. - FY2022-Q3RestatedAnnual report
「The amount of R&D activities across the Group for the first 9 months of the current fiscal year was ¥9.335 million. There were no material changes in the status of the Group's R&D activities during the first 9 months of the current fiscal year.」
R&D activities have continued, and the amount for the first 9 months of the current fiscal year was disclosed as ¥9.335 million, while it was stated that there had been no material changes in the status of the activities. - FY2022-Q2RestatedAnnual report
「The amount of R&D activities across the Group for the first half of the current fiscal year was ¥6.357 million. There were no material changes in the status of the Group's R&D activities during the first half of the current fiscal year.」
R&D expenses of ¥6.357 million were disclosed, and it was stated that there had been no material changes in the status of R&D activities. - FY2022-Q1RestatedAnnual report
「The amount of R&D activities across the Group for the first quarter of the current fiscal year was ¥3.194 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current fiscal year.」
R&D expenses of ¥3.194 million were disclosed, and it was stated that there had been no material changes in the status of R&D activities. - FY2021RestatedAnnual report
「Total R&D expenses included in selling, general and administrative expenses and current-period manufacturing costs were ¥11.895 million.」
Annual R&D expenses of ¥11.895 million related to product launches and the creation of growth products were disclosed. - FY2021-Q3RestatedAnnual report
「The amount of research and development activity conducted by the group as a whole during the nine-month period ended in the third quarter was ¥8.654 million. There were no material changes in the status of the group's research and development activities during the nine-month period ended in the third quarter.」
The cumulative amount of R&D activities disclosed was ¥8.654 million, and it was stated that there had been no material changes in the status of R&D activities. - FY2021-Q2First statedAnnual report
「Research and development investment funds for product launches」
It identifies research and development investment for product launches as a specific use of funds for creating growth products.